Article

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer

2026-04-21

Abstract excerpt

<h4>ABSTRACT</h4> The recent approval of KRAS inhibitors supports the therapeutic value of targeting mutant KRAS cancers. However, clinical efficacy is hindered by both primary and treatment-associated acquired resistance. We applied a CRISPR-Cas9 loss-of-function screen and identified loss of KEAP1 as a resistance mechanism to the KRAS G12D -selective inhibitor MRTX1133 and the RAS(ON) multi-selective inhibito...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c79870de-1b4c-5ba0-9678-3cada6cebad4
DOI: 10.64898/2026.04.18.719329

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerDOI 10.64898/2026.04.18.719329Read

Glutamine-restricted diets restore sensitivity to KRASG12D inhibitor through the reversal of ANXA1 mediated metabolic reprogramming.Semantic proximity Read

In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancerSemantic proximity Read

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerSemantic proximity Read

Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.Semantic proximity Read

Changes in the Transcriptome and Synthetic Lethal Dependencies Following <i>KRAS</i> Mutant Expression Reveal Profound Tissue-SpecificitySemantic proximity Read

ISL2 is an epigenetically silenced tumor suppressor and regulator of metabolism in pancreatic cancerSemantic proximity Read

Survival of pancreatic cancer cells lacking KRAS functionSemantic proximity Read

Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy.Semantic proximity Read

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.Semantic proximity Read

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.Semantic proximity Read

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.Semantic proximity Read

A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.Semantic proximity Read